FDA authorizes Merck’s Covid-19 pill, but stresses its use should be limited
The Food and Drug Administration on Thursday granted emergency authorization to Merck’s molnupiravir, an antiviral pill shown to reduce hospitalization and death in cases of Covid-19, but only in cases where other FDA-authorized Covid treatments are not accessible or clinically appropriate.
The approval comes a day after the FDA authorized an antiviral pill from Pfizer for much broader use in patients as young as 12.
